Zusammenfassung
Die großen Fortschritte bei der Bereitstellung einer großen Zahl unterschiedlicher Blutkomponenten durch die transfusionsmedizinischen Dienste verlangen auch vom behandelnden Arzt eine genaue Kenntnis nicht nur der Wirkungen, sondern auch der Nebenwirkungen und potentiellen Risken der einzelnen Blutkomponenten. Eine ungezielte „breite“ Anwendung von Blutkomponenten ist nicht nur wenig effektiv, sondern erhöht auch das Risiko durch die Blutkomponententherapie. Die Richtlinien einer modernen Blutkomponententherapie verlangen unter einer gesicherte Indikation nach Abwägen des zu erwartenden Nutzens gegen das mögliche Risiko die Anwendung einer möglichst spezifischen Blutkomponente. Zwei Beispiele sollen Nutzen und Risken demonstrieren:
Chapter PDF
Similar content being viewed by others
Literatur
Auberger K (1992) Evaluation of a new protein-C concentrate and comparison of protein-C assays in a child with congenital protein-C deficiency. Ann Hematol 64: 146
Baudo F, DeGasperi A, Cataldo F, Caimi TM, Cattaneo D, Redaelli R, Pannacciulli E, Corti A, Mazza E, Belli L (1992) Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thromb Res 68: 409
Blatt PM, Kingdon HS, McLean G, Roberts HR (1974) Thrombogenic material in prothrombin complex concentrates. Ann Intern Med 81: 766
Blauhut B, Kramar H, Vinazzer H, Bergmann H(1985) Substitution of antithrombin III in shock and DIC: a randomized study. Thromb Res 39: 81
Brackmann HH, Egli H (1981) Treatment of haemophilia patients with inhibitors. In: Seligsohn U, Rimon A, Horoszowski H (eds) Haemophilia. Castle House Publications, Kent, p 113
Brettler DB (1993) Are pure concentrates better? Hemophilia world 8: 4
De Stefano V, Triolo L, De Martini D, Ferrelli R, Mori R, Leone G (1987) Antithrombin III loss in patients with nephrotic syndrome or receiving continuous ambulatory peritoneal dialysis. Evidence of inactive antithrombin III in urine of patients with nephrotic syndrome. J Lab Clin Med 109: 550
Dickneite G, Paques EP (1993) Reduction of mortality with antithrom-bin III in septicemic rats: a study of klebsiella pneumoniae induced sepsis. Thromb Haemostas 69: 9
Dreyfus M, Magny JF, Bridey F, Schwarz HP, Planche C, Dehan M, Tchernia G (1991) Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl j Med 325: 1565
Flaherty Mj,Henderson R, Wener MH, (1989) latrogenic immunization with bovine thrombin: a mechanism for prolonged thrombin times after surgery. Ann Intern Med 111: 631
Goldsmith JAM, Deutsche J, Tang M, Green D (l991) CD4 cells in HIV- 1 infected hemophiliacs: effect of factor VIII concentrates. Thromb Haemostas 66:41
Hedner U,Kisler W (1993) Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 71: 1836
Hellgren M,Tenborn L, Abildgaard U (1982) Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin Gynecol Obstet Invest 14: 127
Hilgartner MW, Knatterud GL and the FEIBA Study Group (1992) The use of factor eight inhibitor by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 61: 36
Hultin MB(I979) Activated clotting factors in factor IX concentrates. Blood 54: 1028
Kario K, Matsuo T,Kodama K, Matsuo M (1992) Prophylactic antithrombin III administration during pregnancy immediately reduces the thrombin hyperactivity of congenital antithrombin III deficiency by forming thrombin-antithrombin III complexes. Thromb Res 66: 509
Keiling A, Holst F, Seitz R, Wallin R, Saldeen T,(l991)Severe factor XIII deficiency in disturbances of synthesis or increased consumption (DZC).Treatment of bleeding complications by factor XIII concentrates Thromb Haemostos 65: 1237
Kingdon HS, Lundblad RL, Veltkamp JJ, Aronson DL(1975) Potentially thrombogenic materials in factor IX concentrates. Thromb Diath Haemorth 33: 61
Laursen B,Mortensen JZ, Frost L, Hansen KB(1981) Disseminated intra vascular Coagulation in hepatic failure treated with antithrombin III. Thromb Res 22: 70
Leone G,Gugliotta L, Mazzucconi MG, De Stefano V, Belmonte MM, Dragoni, F, Specchia G, Centra A,Gamba G, Camera A,Mandelli F, (1993) Evidence of hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E coliL–Asparaginase: a GIMEMA study. Thromb Haemostas 69: 12
MacGregor IR, Ferguson JM, McLaughlin LF, Burnouf T, Prowse CV (1991)Comparison of high purity factor IX concentrates and a prothrombin complex concentrate in canine model of thrombogenicity.Thromb Haemostas 66: 809
Maki M,TeraoT, Ikenoue T, Takemura T, Sekiba,Shirakawa K, Soma H (1987) Clinical evaluation of antithrombin III concentrate (BI 6.OI3) for disseminated intravascular coagulation in obstetrics. Gynecol Obstet Invest 23: 230–240
Makris M, Kitchen S, Russell F, Preston FE (1991) Clinical use and monitoring of activated recombinant factor FVII concenkate (rFVIIa) in haemophilia A patients with factor VIII inhibitors. Thromb Haemostas 65: 64
Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Bottasso B, Simoni L, Rosenberg RD (1990) Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood 76: 254
Mannucci PM, Gringeri A, de Biasi R, Baudo F, Morfini M, Ciavarella N (1992) Immune status of asymptomatic HIV-infected hemophiliacs: randomized, prospective, two-year comparison of treatment with a high-purity or an intermediate-purity factor VIII concentrate. Thromb Haemostas 67: 310
Marassi A, Manzullo V, di Carlo V, Mannucci PM (1978) Thromboem-bolism following prothrombin complex concentrates and major surgery in liver disease. Thromb Haemostas 39: 787
Menache D, O’Malley JP, Schorr JB, Wagner B, Williams C, the Cooperative Study Group (1990) Evaluation of the safety, recovery, halflife, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Blood 75: 33
Muntean W, Finding K, Gamillscheg A, Zenz W (1992) Multiple thromboses and coumarin-induced skin necrosis in a young child with antiphospholipid antibodies. Thromb Haemorrh Disord 5: 43
Muntean W, Finding K, Gamillscheg A, Zenz W (1992) Multiple thromboses and coumarin-induced skin necrosis in a young child with antiphospholipid antibodies. Thromb Haemorrh Disord 5: 43
Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER (1988) Thrombolytic therapy with tissue plasminogen activator or skeptokinase induces transient thrombin activity. Blood 72: 616
Rake MO, Pannell G, Flute PT, Williams R (1970) Inkavascular coagulation in acute hepatic necrosis. Lancet i: 533
Rousou J, Levitsky S, Gonzalez-Lavin L, Cosgrove D, Magilligan D, Weldon C, Hiebert C, Hess P, Joyce L, Bergsland J, Gazzangia A (1989) Randomized clinical trial of fibrin sealant in patients undergoing resternotomy or cardiac operations. J Thor Cardiovasc Surg 97: 2
Smid WM, vdMeer T, Smit JW, Halie MR (1993) The course of preexistent immune abnormalities in HIV negative haemophiliacs keated for two years with a monoclonal purified factor VIII concentrate. Thromb Haemostas 69: 306
Schulman S, Tengborn L (1992) Treatment of venous thromboembolism in patients with congenital deficiency of antithrombin III. Thromb Haemostas 68: 634
Schwartz RS, Bauer KA, Rosenberg RD (1989) Clinical experience with antithrombin III concentrate in keatment of congenital and acquired deficiency of antithrombin. Am j Med 87 [Suppl 3 B]: 53
Stricken RB, Lane PK, Leffert JD, Rodgers GM, Shaman MA, Corash L (1988) Development of antithrombin antibodies following surgery in patients with prosthetic cardiac valves. Blood 72: 1375
Vinazzer H (1989) Therapeutic use of antithrombin III in shock and disseminated intraavascular coagulation. Semin Thromb Hemostas 15: 347
Zaunschirm A, Muntean W (1986) Correction of hemostatic imbalances induced by L-Asparaginase therapy in children with acute lymphoblastic leukemia. Ped Hematol Oncol 3: 19
Zehnder JL, Leung LLK (1990) Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 76: 2011
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer-Verlag/Wien
About this paper
Cite this paper
Muntean, W. (1997). Indikationen für plasmatische Hämoderivate. In: Lanzer, G. (eds) Plasmaderivate in der Therapie mit Blutkomponenten. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6865-3_4
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6865-3_4
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83016-1
Online ISBN: 978-3-7091-6865-3
eBook Packages: Springer Book Archive